Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immuron CEO, Steven Lydeamore to present at H.C. Wainwright By: Immuron Limited via GlobeNewswire September 11, 2023 at 06:00 AM EDT MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th. The webcast to this presentation will be available here at 7am Eastern Daylight Time / 9pm Australian Eastern Standard time on September 11th. A copy of the presentation being made at the H.C. Wainwright 25th Annual Global Investment Conference is available on the Company’s website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven LydeamoreChief Executive OfficerPh: +61 (0)3 9824 5254info@immuron.com About ImmuronImmuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. For more information visit: http://www.immuron.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright By: Immuron Limited via GlobeNewswire September 11, 2023 at 06:00 AM EDT MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th. The webcast to this presentation will be available here at 7am Eastern Daylight Time / 9pm Australian Eastern Standard time on September 11th. A copy of the presentation being made at the H.C. Wainwright 25th Annual Global Investment Conference is available on the Company’s website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven LydeamoreChief Executive OfficerPh: +61 (0)3 9824 5254info@immuron.com About ImmuronImmuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. For more information visit: http://www.immuron.com
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th. The webcast to this presentation will be available here at 7am Eastern Daylight Time / 9pm Australian Eastern Standard time on September 11th. A copy of the presentation being made at the H.C. Wainwright 25th Annual Global Investment Conference is available on the Company’s website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven LydeamoreChief Executive OfficerPh: +61 (0)3 9824 5254info@immuron.com About ImmuronImmuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. For more information visit: http://www.immuron.com
